WA
The startup develops antibody-drug conjugate (ADC) technologies utilizing proprietary highly active payloads (PHAP) to create targeted biopharmaceuticals for oncology and autoimmune diseases. Their products aim to improve treatment efficacy and patient outcomes in these critical medical areas.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antibody-drug conjugate (ADC) technologies utilizing proprietary highly active payloads (PHAP) to create targeted biopharmaceuticals for oncology and autoimmune diseases. Their products aim to improve treatment efficacy and patient outcomes in these critical medical areas.